Sabry Takes BD Reins at Roche's gRED
Executive Summary
The recent appointment of James Sabry, MD, PhD, as Genentech's new head of business development is Roche's latest attempt to retain the spirit of the once-independent biotech icon.
You may also be interested in...
Genentech's New Deal Maker
In a wide-ranging interview just four days after joining Genentech, the biotech's new head of business development outlines his team's mission, which emphasizes early-stage novel assets arising from academia and biotech.
Business Development at Roche and Genentech: An Interview with Joe McCracken and Dan Zabrowski
What does Roche's privatization of Genentech mean for the companies' business development organizations and current and future partners? We recently sat down with the company's two business development chiefs to find out.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.